fenofibric acid has been researched along with gw 9578 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brown, PJ; Chapman, JM; Kliewer, SA; Koble, CS; Lehmann, JM; Lewis, MC; Moore, LB; Plunket, KD; Sundseth, SS; Willson, TM; Wilson, JG; Winegar, DA; Wu, Z | 1 |
| Barr, RJ; Bean, JS; Bensch, WR; Dominianni, SJ; Huang, N; Kauffman, RF; Luffer-Atlas, D; Maise, DE; Mantlo, NB; Mayhugh, D; Montrose-Rafizadeh, C; Osborne, J; Rungta, D; Saeed, A; Singh, J; Thompson, RC; Wang, X; Xu, Y; Yumibe, NP; Zink, RW | 1 |
2 other study(ies) available for fenofibric acid and gw 9578
| Article | Year |
|---|---|
A ureido-thioisobutyric acid (GW9578) is a subtype-selective PPARalpha agonist with potent lipid-lowering activity.
Topics: Animals; Butyrates; DNA-Binding Proteins; Fenofibrate; Humans; Hypolipidemic Agents; Lipid Metabolism; Male; Mice; Nuclear Proteins; Phenylurea Compounds; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Transcription Factors; Zinc Fingers | 1999 |
Design and synthesis of a potent and selective triazolone-based peroxisome proliferator-activated receptor alpha agonist.
Topics: Administration, Oral; Animals; Apolipoprotein A-I; Binding, Competitive; Biological Availability; Cell Line; Dogs; Drug Design; Humans; Mice; Mice, Transgenic; Propionates; Radioligand Assay; Rats; Receptors, Cytoplasmic and Nuclear; Structure-Activity Relationship; Transcription Factors; Transfection; Triazoles | 2003 |